Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
Website: http://www.novartis.com/
About Novartis
At Novartis, we are driven by a single mission: to discover new ways to improve and extend people’s lives. Through science-based innovation we address some of society’s most challenging healthcare issues. Working to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Novartis focuses on innovative patent-protected medicines, generics and eye care products – segments where we have global reach and strong relations with our customers. Research and development (R&D) sits at the core of our business and central to our strategy. Our global organizations for manufacturing, business services and other functions help increase efficiency and promote excellence.
Reimagine what you could do at Novartis.
1600 articles with Novartis
-
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
-
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Emgality (galcanezumab-gnlm) for migraine prevention.
-
Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China
9/27/2018
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.
-
Verastem Gets FDA Approval for Leukemia Drug, Will Make It Immediately Available to Patients
9/25/2018
Shares of Verastem closed out Monday trading on a positive note and continues to climb in the premarket following the greenlight for leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. -
Swiss pharmaceutical giant Novartis plans to slash approximately 2,200 jobs in Switzerland over the next four years.
-
Akcea Therapeutics, based in Cambridge, Massachusetts, and Ionis Pharmaceuticals, headquartered in Carlsbad, California, released positive topline data from a Phase II trial of AKCEA-APO(a)-LRx in cardiovascular disease and lipoprotein(a).
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
-
The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries’ Ajovy (fremanezumab) to prevent migraine on Friday, September 16.
-
Although Hurricane Florence has been downgraded to a Category 2, the massive storm has the potential to dump enough rain to produce catastrophic flooding across the Carolinas. Despite the downgrade, Pfizer is taking no chances and will close its North Carolina injectables plant ahead of the storm.
-
CODA Biotherapeutics launched in South San Francisco with a $19 million Series A financing.
-
In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.
-
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...
9/6/2018
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS). -
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.
-
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
-
Maryland-based REGENXBIO is expanding its gene therapy pipeline to include a new treatment for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease.
-
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
8/28/2018
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
-
The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.